$ACUR
ACURA PHARMACEUTICALS, INC Stock $acur

$acur Overview Financials Valuation SEC Filings Company Website

2018 Q2 Form 10-Q Financial Statement

#000114420418044691 Filed on August 14, 2018

Income Statement

Concept	2018 Q2	2017 Q2
Revenue	$76.00K	$92.00K
YoY Change	-17.39%	-64.2%
Cost Of Revenue	$0.00	$0.00
YoY Change		-100.0%
Gross Profit	$0.00	$90.00K
YoY Change	-100.0%	-43.75%
Gross Profit Margin	0.0%	97.83%
Selling, General & Admin	$846.0K	$1.063M
YoY Change	-20.41%	-41.21%
% of Gross Profit		1181.11%
Research & Development	$477.0K	$1.020M
YoY Change	-53.24%	-27.3%
% of Gross Profit		1133.33%
Depreciation & Amortization	$71.00K	$70.00K
YoY Change	1.43%	-22.22%
% of Gross Profit		77.78%
Operating Expenses	$1.323M	$2.083M
YoY Change	-36.49%	-35.13%
Operating Profit	-$1.247M	-$1.991M
YoY Change	-37.37%	-35.34%
Interest Expense	$14.00K	$158.0K
YoY Change	-91.14%	-32.19%
% of Operating Profit
Other Income/Expense, Net		$0.00
YoY Change		-100.0%
Pretax Income	-$1.261M	-$2.149M
YoY Change	-41.32%	-34.64%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$1.261M	-$2.149M
YoY Change	-41.32%	-34.64%
Net Earnings / Revenue	-1659.21%	-2335.87%
Basic Earnings Per Share	-$0.06	-$0.18
Diluted Earnings Per Share	-$0.06	-$0.18
COMMON SHARES
Basic Shares Outstanding	21.10M shares	11.97M shares
Diluted Shares Outstanding	21.10M shares	11.97M shares

Balance Sheet

Concept	2018 Q2	2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$668.0K	$1.080M
YoY Change	-38.15%	-84.07%
Cash & Equivalents	$568.0K	$1.079M
Short-Term Investments	$0.00
Other Short-Term Assets	$154.0K	$3.060M
YoY Change	-94.97%	524.49%
Inventory		$0.00
Prepaid Expenses
Receivables		$0.00
Other Receivables		$50.00K
Total Short-Term Assets	$916.0K	$4.190M
YoY Change	-78.14%	-45.43%
LONG-TERM ASSETS
Property, Plant & Equipment	$641.0K	$720.0K
YoY Change	-10.97%	-28.71%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$1.897M	$2.050M
YoY Change	-7.46%	-19.42%
TOTAL ASSETS
Total Short-Term Assets	$916.0K	$4.190M
Total Long-Term Assets	$1.897M	$2.050M
Total Assets	$2.813M	$6.240M
YoY Change	-54.92%	-38.96%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$662.0K	$580.0K
YoY Change	14.14%	253.66%
Accrued Expenses	$795.0K	$720.0K
YoY Change	10.42%	-10.45%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.505M	$2.860M
YoY Change	-47.38%	8.79%
Total Short-Term Liabilities	$4.002M	$4.500M
YoY Change	-11.07%	14.13%
LONG-TERM LIABILITIES
Long-Term Debt	$1.429M	$1.430M
YoY Change	-0.07%	-65.67%
Other Long-Term Liabilities	$8.000K	$630.0K
YoY Change	-98.73%	31.25%
Total Long-Term Liabilities	$1.437M	$2.060M
YoY Change	-30.24%	-50.54%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.002M	$4.500M
Total Long-Term Liabilities	$1.437M	$2.060M
Total Liabilities	$5.439M	$6.560M
YoY Change	-17.09%	-23.59%
SHAREHOLDERS EQUITY
Retained Earnings	-$383.1M
YoY Change
Common Stock	$380.5M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$2.626M	-$320.0K
YoY Change
Total Liabilities & Shareholders Equity	$2.813M	$6.240M
YoY Change	-54.92%	-38.96%

Cashflow Statement

Concept	2018 Q2	2017 Q2
OPERATING ACTIVITIES
Net Income	-$1.261M	-$2.149M
YoY Change	-41.32%	-34.64%
Depreciation, Depletion And Amortization	$71.00K	$70.00K
YoY Change	1.43%	-22.22%
Cash From Operating Activities	-$964.0K	-$2.090M
YoY Change	-53.88%	-41.46%
INVESTING ACTIVITIES
Capital Expenditures		$0.00
YoY Change		-100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00
YoY Change		-100.0%
Cash From Investing Activities	$0.00	$0.00
YoY Change		-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	762.0K	-670.0K
YoY Change	-213.73%	8.06%
NET CHANGE
Cash From Operating Activities	-964.0K	-2.090M
Cash From Investing Activities	0.000	0.000
Cash From Financing Activities	762.0K	-670.0K
Net Change In Cash	-202.0K	-2.760M
YoY Change	-92.68%	13700.0%
FREE CASH FLOW
Cash From Operating Activities	-$964.0K	-$2.090M
Capital Expenditures		$0.00
Free Cash Flow		-$2.090M
YoY Change		-41.29%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018Q2	us-gaap	Deposits Assets Current DepositsAssetsCurrent	100000	USD
CY2017Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	0	USD
	acur	Interest Expense Term Loan One InterestExpenseTermLoanOne	281000	USD
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
	us-gaap	Share Based Compensation ShareBasedCompensation	122000	USD
CY2018Q2	acur	Interest Expense Term Loan Two InterestExpenseTermLoanTwo	8000	USD
CY2017Q2	acur	Interest Expense Term Loan Two InterestExpenseTermLoanTwo	0	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	233000	USD
CY2018Q2	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	13000	USD
CY2017Q4	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	16000	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	187000	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	337000	USD
CY2018Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	88000	USD
CY2017Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	159000	USD
CY2018Q2	us-gaap	Assets Current AssetsCurrent	916000	USD
	acur	Interest Expense Term Loan Two InterestExpenseTermLoanTwo	8000	USD
	acur	Interest Expense Term Loan Two InterestExpenseTermLoanTwo	0	USD
	us-gaap	Net Income Loss NetIncomeLoss	-2755000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-1744000	USD
CY2018Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	34000	USD
	acur	Interest Expense Debt Discount InterestExpenseDebtDiscount	24000	USD
	acur	Interest Expense Debt Discount InterestExpenseDebtDiscount	37000	USD
CY2018Q2	acur	Interest Expense Debt Discount InterestExpenseDebtDiscount	13000	USD
CY2017Q2	acur	Interest Expense Debt Discount InterestExpenseDebtDiscount	17000	USD
CY2018Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21034000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	20796000	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	20796000	shares
CY2018Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21034000	shares
CY2018Q2	us-gaap	Accumulated Amortization Deferred Finance Costs AccumulatedAmortizationDeferredFinanceCosts	879000	USD
CY2017Q4	us-gaap	Accumulated Amortization Deferred Finance Costs AccumulatedAmortizationDeferredFinanceCosts	776000	USD
CY2018Q2	acur	Accrued Cost Sharing Expenses AccruedCostSharingExpenses	412000	USD
CY2017Q4	acur	Accrued Cost Sharing Expenses AccruedCostSharingExpenses	328000	USD
CY2018Q2	acur	Interest Expense Term Loan One InterestExpenseTermLoanOne	63000	USD
CY2017Q2	acur	Interest Expense Term Loan One InterestExpenseTermLoanOne	133000	USD
	acur	Interest Expense Term Loan One InterestExpenseTermLoanOne	145000	USD
CY2018Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	154000	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	275000	USD
CY2018Q2	us-gaap	Cumulative Effect Of New Accounting Principle In Period Of Adoption CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	0	USD
	acur	Contract Balance And Performance Obligationsdescription ContractBalanceAndPerformanceObligationsdescription	The Company’s reported contract assets and contract liability balances under the license and collaboration agreements at either June 30, 2018 or December 31, 2017 was $0.00.
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	274000	USD
CY2018Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	76000	USD
CY2017Q2	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	9000	USD
CY2018Q2	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	4000	USD
	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	19000	USD
	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	10000	USD
CY2018Q2	acur	Accrued Other Professional Fees Current AccruedOtherProfessionalFeesCurrent	118000	USD
CY2017Q4	acur	Accrued Other Professional Fees Current AccruedOtherProfessionalFeesCurrent	326000	USD
	acur	Provision For Sales Returns ProvisionForSalesReturns	0	USD
	acur	Provision For Sales Returns ProvisionForSalesReturns	49000	USD
	dei	Document Period End Date DocumentPeriodEndDate	2018-06-30
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	36000	USD
CY2018Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2018Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	568000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2220000	USD
CY2018Q2	acur	Royalty Receivable RoyaltyReceivable	94000	USD
CY2017Q4	acur	Royalty Receivable RoyaltyReceivable	71000	USD
CY2018Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2018Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	77000	USD
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	70000	USD
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	38000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	47000	USD
CY2018Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	127000	USD
CY2017Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	149000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	2566000	USD
CY2018Q2	us-gaap	Income Taxes Receivable Noncurrent IncomeTaxesReceivableNoncurrent	135000	USD
CY2017Q4	us-gaap	Income Taxes Receivable Noncurrent IncomeTaxesReceivableNoncurrent	135000	USD
CY2018Q2	acur	Other Accrued Taxes Current OtherAccruedTaxesCurrent	14000	USD
CY2017Q4	acur	Other Accrued Taxes Current OtherAccruedTaxesCurrent	14000	USD
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Registrant Name EntityRegistrantName	ACURA PHARMACEUTICALS, INC
CY2018Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	169000000	USD
CY2017Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	168000000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	74000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2018Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	795000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	939000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	-27000	USD
CY2018Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	641000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	679000	USD
CY2018Q2	acur	Cost Of Sales Excluding Inventory Write Down CostOfSalesExcludingInventoryWriteDown	0	USD
CY2017Q2	acur	Cost Of Sales Excluding Inventory Write Down CostOfSalesExcludingInventoryWriteDown	0	USD
	acur	Cost Of Sales Excluding Inventory Write Down CostOfSalesExcludingInventoryWriteDown	0	USD
	acur	Cost Of Sales Excluding Inventory Write Down CostOfSalesExcludingInventoryWriteDown	128000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1127000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1731000	USD
CY2018Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	477000	USD
CY2017Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1020000	USD
CY2018Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1121000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1224000	USD
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35	pure
	dei	Entity Central Index Key EntityCentralIndexKey	0000786947
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	34000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	56000	USD
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2017	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	1000000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-23000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-1261000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-2149000	USD
CY2018Q3	us-gaap	Debt Instrument Basis Spread On Variable Rate1 DebtInstrumentBasisSpreadOnVariableRate1	0.02	pure
CY2018Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	846000	USD
CY2017Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1063000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1789000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2359000	USD
CY2018Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2512000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2512000	USD
CY2018Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1871000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1833000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	2916000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	4218000	USD
CY2018Q2	us-gaap	Costs And Expenses CostsAndExpenses	1323000	USD
CY2017Q2	us-gaap	Costs And Expenses CostsAndExpenses	2083000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	122000	USD
	acur	Increase Decrease In Collaboration Revenue Receivable IncreaseDecreaseInCollaborationRevenueReceivable	0	USD
	acur	Increase Decrease In Collaboration Revenue Receivable IncreaseDecreaseInCollaborationRevenueReceivable	-78000	USD
CY2017	acur	Operating Loss Carryforwards Expiration Term OperatingLossCarryforwardsExpirationTerm	P20Y
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Trading Symbol TradingSymbol	ACUR
CY2017	acur	Operating Loss Carry Forwards Expiration Year OperatingLossCarryForwardsExpirationYear	2037
	acur	Increase Decrease In Royalty Receivable IncreaseDecreaseInRoyaltyReceivable	23000	USD
	acur	Increase Decrease In Royalty Receivable IncreaseDecreaseInRoyaltyReceivable	0	USD
CY2018Q2	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	21034000	shares
CY2017Q2	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	11883000	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	21034000	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	11884000	shares
	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	34000	USD
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1247000	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1991000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2642000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1409000	USD
CY2018Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	662000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3000	USD
	us-gaap	Interest Expense InterestExpense	113000	USD
	us-gaap	Interest Expense InterestExpense	335000	USD
CY2018Q2	us-gaap	Interest Expense InterestExpense	14000	USD
CY2017Q2	us-gaap	Interest Expense InterestExpense	158000	USD
CY2017Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	32000	USD
	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	34000	shares
	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	54000	shares
CY2018Q2	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	67000	shares
CY2017Q2	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	83000	shares
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-103000	USD
CY2017Q4	us-gaap	Tax Credit Carryforward Amount TaxCreditCarryforwardAmount	150000	USD
CY2018Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	21033528000	shares
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-121000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	294000	USD
CY2018Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21101000	shares
CY2017Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11966000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21068000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11938000	shares
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	-2626000	USD
CY2018Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1261000	USD
CY2017Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2149000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2755000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1744000	USD
CY2018Q2	us-gaap	Interest Payable Current InterestPayableCurrent	767000	USD
CY2017Q4	us-gaap	Interest Payable Current InterestPayableCurrent	700000	USD
CY2018Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	19000	USD
CY2017Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	41000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2018Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2017Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2017Q3	acur	Number Of Common Stock Need To Hold To Designate As Director NumberOfCommonStockNeedToHoldToDesignateAsDirector	600000	shares
	acur	Increase Decrease In Refundable Deposits IncreaseDecreaseInRefundableDeposits	100000	USD
	acur	Increase Decrease In Refundable Deposits IncreaseDecreaseInRefundableDeposits	0	USD
CY2018Q2	acur	Accrued Cost Sharing Expenses Clinical Studies AccruedCostSharingExpensesClinicalStudies	412000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	659000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	505000	USD
CY2013Q4	us-gaap	Secured Debt SecuredDebt	10000000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	24000	USD
CY2018Q2	acur	Sales Returns Liability Current SalesReturnsLiabilityCurrent	254000	USD
CY2017Q4	acur	Sales Returns Liability Current SalesReturnsLiabilityCurrent	254000	USD
CY2018Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	1505000	USD
CY2017Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	2694000	USD
CY2018Q2	acur	Working Capital WorkingCapital	3100000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-144000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-12000	USD
CY2018Q2	us-gaap	Gain Contingency Unrecorded Amount GainContingencyUnrecordedAmount	10000000	USD
CY2018Q2	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	10000000	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	75000	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	105000	USD
CY2017Q4	acur	Debt Instrument Issuance Costs DebtInstrumentIssuanceCosts	14000	USD
CY2018Q2	us-gaap	Liabilities Current LiabilitiesCurrent	4002000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4631000	USD
CY2018Q2	us-gaap	Liabilities Liabilities	5439000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	4631000	USD
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	5200000	USD
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.15
CY2018Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
CY2017Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
CY2017Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4000000	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	10000	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	11000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1934000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-789000	USD
	acur	Amortization Expense Of Debt Instrument Issuance Costs AmortizationExpenseOfDebtInstrumentIssuanceCosts	10000	USD
CY2018Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.06
CY2017Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.18
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.15
CY2018Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q2	acur	Debt Instrument Issuance Costs DebtInstrumentIssuanceCosts	4000	USD
CY2018Q2	us-gaap	Long Term Debt LongTermDebt	2934000	USD
CY2018Q2	us-gaap	Common Stock Value CommonStockValue	210000	USD
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	208000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	103000	USD
	acur	Proceeds From Sale Of Inventory ProceedsFromSaleOfInventory	0	USD
	acur	Proceeds From Sale Of Inventory ProceedsFromSaleOfInventory	206000	USD
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0	USD
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0	USD
CY2018Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	380299000	USD
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	380145000	USD
CY2018Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21101000	shares
CY2017Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11966000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21068000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11938000	shares
CY2018Q2	acur	Cash Cash Equivalents And Refundable Deposits CashCashEquivalentsAndRefundableDeposits	700000	USD
CY2018Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-383135000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-380380000	USD
CY2018Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	34000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	309000	USD
	acur	Agreement Termination Notice Description AgreementTerminationNoticeDescription	Egalet may terminate the Egalet Agreement for convenience on 120 days prior written notice, which termination may not occur prior to the second anniversary of Egalet’s launch of Oxaydo. Termination does not affect a party’s rights accrued prior thereto, but there are no stated payments in connection with termination other than payments of obligations previously accrued. For all terminations (but not expiration), the Egalet Agreement provides for the transition of development and marketing of Oxaydo from Egalet to us, including the conveyance by Egalet to us of the trademarks and all regulatory filings and approvals relating to Oxaydo, and for Egalet’s supply of Oxaydo for a transition period.<table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2813000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4604000	USD
CY2013Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	10000000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	2000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0	USD
CY2018Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3517000	shares
CY2017Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1576000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3517000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1576000	shares
CY2013Q4	acur	Debt Default Long Term Debt Percentage DebtDefaultLongTermDebtPercentage	0.1335	pure
	acur	Increase Decrease In Sales Return Liability IncreaseDecreaseInSalesReturnLiability	0	USD
	acur	Increase Decrease In Sales Return Liability IncreaseDecreaseInSalesReturnLiability	49000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-1652000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-1602000	USD
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5181000	USD
CY2017Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3579000	USD
CY2018Q2	us-gaap	Debt Instrument Fee Amount DebtInstrumentFeeAmount	50000	USD
CY2017Q1	acur	License Agreement Option Products Description LicenseAgreementOptionProductsDescription	In addition, MainPointe has the option to add to the MainPointe Agreement certain additional products, or Option Products, containing PSE and utilizing the Impede technology for a fee of $500 thousand per product (for all product strengths). Such Option Products include the product candidate Loratadine with pseudoephedrine. If the territory has been expanded prior to the exercise of a product option, the option fee will be increased to $750 thousand per product. If the territory is expanded after the payment of the $500 thousand product option fee, a one-time $250 thousand fee will be due for each product. If a third party is interested in developing or licensing rights to an Option Product, MainPointe must exercise its option for that product or its option rights for such product will terminate.<table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	acur	Debt Consulting Placement Fee DebtConsultingPlacementFee	100000	USD
	us-gaap	Interest Paid Net InterestPaidNet	78000	USD
	us-gaap	Interest Paid Net InterestPaidNet	176000	USD
CY2017Q2	us-gaap	Cash Cash	1077000	USD
CY2018Q2	us-gaap	Cash Cash	568000	USD
CY2015Q1	acur	Debt Instrument Cash Maintenance DebtInstrumentCashMaintenance	2500000	USD
CY2018Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	USD
CY2017Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	2000	USD
	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	260000	USD
CY2018Q2	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.1016	pure
CY2016Q4	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	6000000	USD
CY2017Q3	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	4000000	USD
CY2017Q1	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	2500000	USD
CY2018Q2	acur	Revenue From License Fee RevenueFromLicenseFee	0	USD
CY2017Q2	acur	Revenue From License Fee RevenueFromLicenseFee	0	USD
	acur	Revenue From License Fee RevenueFromLicenseFee	0	USD
	acur	Revenue From License Fee RevenueFromLicenseFee	2500000	USD
CY2018Q2	us-gaap	Assets Assets	2813000	USD
CY2017Q4	us-gaap	Assets Assets	4604000	USD
CY2018Q2	acur	Interest Payable Noncurrent InterestPayableNoncurrent	8000	USD
CY2017Q4	acur	Interest Payable Noncurrent InterestPayableNoncurrent	0	USD
CY2018Q2	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	1429000	USD
CY2017Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	0	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	1500000	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
	us-gaap	Repayments Of Debt RepaymentsOfDebt	1220000	USD
	us-gaap	Repayments Of Debt RepaymentsOfDebt	1122000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	282000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1122000	USD
CY2018Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	0	USD
CY2017Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	2500000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	74000	USD
CY2018Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	82000	USD
CY2018Q2	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	74000	USD
CY2017Q2	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2017Q2	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	1000	USD
CY2018Q2	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	0	USD
	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	2000	USD
	us-gaap	Investment Income Nonoperating InvestmentIncomeNonoperating	0	USD
	us-gaap	Interest Expense InterestExpense	113000	USD
	us-gaap	Interest Expense InterestExpense	335000	USD
CY2018Q2	us-gaap	Interest Expense InterestExpense	14000	USD
CY2017Q2	us-gaap	Interest Expense InterestExpense	158000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P5M
CY2018Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	66000	USD
CY2017Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	129000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	142000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	258000	USD
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.06
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.18
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.13
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.15
CY2018Q2	acur	Other Sale Revenues Net OtherSaleRevenuesNet	0	USD
CY2017Q2	acur	Other Sale Revenues Net OtherSaleRevenuesNet	23000	USD
	acur	Other Sale Revenues Net OtherSaleRevenuesNet	0	USD
	acur	Other Sale Revenues Net OtherSaleRevenuesNet	59000	USD
CY2018Q2	acur	Revenue From Royalty RevenueFromRoyalty	76000	USD
CY2017Q2	acur	Revenue From Royalty RevenueFromRoyalty	69000	USD
	acur	Revenue From Royalty RevenueFromRoyalty	274000	USD
	acur	Revenue From Royalty RevenueFromRoyalty	143000	USD
CY2018Q2	acur	Sale Revenue Goods Net SaleRevenueGoodsNet	0	USD
CY2017Q2	acur	Sale Revenue Goods Net SaleRevenueGoodsNet	0	USD
	acur	Sale Revenue Goods Net SaleRevenueGoodsNet	0	USD
	acur	Sale Revenue Goods Net SaleRevenueGoodsNet	107000	USD
	us-gaap	Revenues Revenues	274000	USD
	us-gaap	Revenues Revenues	2809000	USD
CY2018Q2	us-gaap	Revenues Revenues	76000	USD
CY2017Q2	us-gaap	Revenues Revenues	92000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	103000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	3000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	103000	USD

Files In Submission

Name	View Source	Status
0001144204-18-044691-index-headers.html	Edgar Link	pending
0001144204-18-044691-index.html	Edgar Link	pending
0001144204-18-044691.txt	Edgar Link	pending
0001144204-18-044691-xbrl.zip	Edgar Link	pending
acur-20180630.xml	Edgar Link	completed
acur-20180630.xsd	Edgar Link	pending
acur-20180630_cal.xml	Edgar Link	unprocessable
acur-20180630_def.xml	Edgar Link	unprocessable
acur-20180630_lab.xml	Edgar Link	unprocessable
acur-20180630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tv500081_10q.htm	Edgar Link	pending
tv500081_ex10-35.htm	Edgar Link	pending
tv500081_ex10-36.htm	Edgar Link	pending
tv500081_ex10-37.htm	Edgar Link	pending
tv500081_ex10-38.htm	Edgar Link	pending
tv500081_ex31-1.htm	Edgar Link	pending
tv500081_ex31-2.htm	Edgar Link	pending
tv500081_ex32-1.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ACUR
ACURA PHARMACEUTICALS, INC Stock $acur

2018 Q2 Form 10-Q Financial Statement

#000114420418044691 Filed on August 14, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ACUR ACURA PHARMACEUTICALS, INC Stock $acur

2018 Q2 Form 10-Q Financial Statement

#000114420418044691 Filed on August 14, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ACUR
ACURA PHARMACEUTICALS, INC Stock $acur